<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37866620</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</Title><ISOAbbreviation>J Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>Relevance of complement immunity with brain fog in patients with long COVID.</ArticleTitle><Pagination><StartPage>236</StartPage><EndPage>241</EndPage><MedlinePgn>236-241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiac.2023.10.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1341-321X(23)00261-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This study aimed to elucidate the prevalence and clinical characteristics of patients with long COVID (coronavirus disease 2019), especially focusing on 50% hemolytic complement activity (CH50).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective observational study focused on patients who visited Okayama University Hospital (Japan) for the treatment of long COVID between February 2021 and March 2023. CH50 levels were measured using liposome immunometric assay (Autokit CH50 Assay, FUJIFILM Wako Pure Chemical Corporation, Japan); high CH50 was defined as &#x2265;59 U/mL. Univariate analyses assessed differences in the clinical background, long COVID symptoms, inflammatory markers, and clinical scores of patients with normal and high CH50. Logistic regression model investigated the association between high CH50 levels and these factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 659 patients who visited our hospital, 478 patients were included. Of these, 284 (59.4%) patients had high CH50 levels. Poor concentration was significantly more frequent in the high CH50 group (7.2% vs. 13.7%), whereas no differences were observed in other subjective symptoms (fatigue, headache, insomnia, dyspnea, tiredness, and brain fog). Multivariate analysis was performed on factors that could be associated with poor concentration, suggesting a significant relationship to high CH50 levels (adjusted odds ratio [aOR], 2.70; 95% confidence interval [CI], 1.33-5.49). Also, high CH50 was significantly associated with brain fog (aOR, 1.66; 95% CI, 1.04-2.66).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High CH50 levels were frequently reported in individuals with long COVID, indicating a relationship with brain fog. Future in-depth research should examine the pathological role and causal link between complement immunity and the development of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hagiya</LastName><ForeName>Hideharu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Okayama University Hospital, Okayama, 700-8558, Japan. Electronic address: hagiya@okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokumasu</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunada</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Okayama University Hospital, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Infect Chemother</MedlineTA><NlmUniqueID>9608375</NlmUniqueID><ISSNLinking>1341-321X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015941" MajorTopicYN="N">Complement Hemolytic Activity Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005222" MajorTopicYN="N">Mental Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complement immunity</Keyword><Keyword MajorTopicYN="N">Complement system</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>10</Day><Hour>14</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>22</Day><Hour>19</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37866620</ArticleId><ArticleId IdType="doi">10.1016/j.jiac.2023.10.016</ArticleId><ArticleId IdType="pii">S1341-321X(23)00261-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>